Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Citizens BancShares Inc (FCNCA) vs Smith & Nephew plc (SNN) Price & Performance

First Citizens BancShares IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

First Citizens BancShares Inc vs Smith & Nephew plc — how do they compare? First Citizens BancShares Inc trades at $2,077.31 (market cap $22.94B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: First Citizens BancShares Inc is far larger — about 2.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and Smith & Nephew plc for 121 Days on average.

FCNCASNN
Market Cap
$22.94B$11.10B
Volume
91,6681,051,703
Sector
Sector/ThematicHealth
52-Week High
$2.29K$37.17
52-Week Low
$1.64K$26.42
Typical Hold Time
29 Days121 Days
Dividend Yield
0.41%2.95%
Enterprise Value
—$14.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Citizens BancShares Inc

First Citizens BancShares (FCNCA) trades at $2,071.56, down 0.79% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with a P/E of 11.11 and net income margin of 25.23%, and has beaten EPS estimates for the last three quarters. Recent corporate actions include a $2.10 dividend and expansion through branch acquisitions and new financing initiatives.

The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but near-term technical weakness and high institutional hold ratings suggest caution. Key risks include execution of growth initiatives and broader economic pressures on banking.

Smith & Nephew plc

SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.

The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Citizens BancShares Inc

First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.

Read more on FCNCA →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →